Correlation between clinical response to antiandrogenic therapy and occurrence of receptors in human prostatic cancer

Martelli, A.; Grilli, Sandro; Soli, M.; Giovanni, Carla De; Bercovich, E.; Galli, M. C.; Prodi, Giorgio

doi:10.1016/0090-4295(80)90035-7

Cited by 14 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using a chemical method for the determination of the androphilic protein, a correlation was already shown between the amount of androphilic protein and respon siveness to endocrine therapy in prostatic cancer [24,25], The present study also showed a significant relationship between the fluorescence of R 1881-CMO-BSA-FITC in the tissues and the responsiveness of the patients to endo crine therapy. Moreover, the fluorescence was correlated with the histologic grade of the cancer, which is well known as an important factor of prognosis [26].…”

Section: Discussionsupporting

confidence: 52%

Histochemical Observation of R1881–Binding Protein in Human Prostatic Cancer

Matsumura¹,

Naito²,

Yamaguchi³

et al. 1983

Urol Int

View full text Add to dashboard Cite

A conjugate of fluorescein isothiocyanate and bovine serum albumin bound with R 1881-3-carboxymethyloxime was used to visualize the location of androphilic proteins in tissues from patients with prostatic cancer. The fluorescence was located in the carcinoma cells but not in the stroma. Although intensity of the staining was varied in fluorescence-positive cases, almost all carcinoma cells were stained. On the contrary, positively stained cells were scarcely observed in fluorescence-negative cancer. Among 46 cases of untreated prostatic cancer examined, 76% were fluorescence-positive. 7 cases out of 9 who had relapsed from endocrine therapy showed negative fluorescence. It was concluded that the fluorescence in the tissue sections of the untreated prostatic cancer were well correlated with the histologic grade, and that fluorescence-positive cases had responded well to the endocrine therapy, as judged 6 months after the start of treatment.

show abstract

Section: Discussionsupporting

confidence: 52%

Histochemical Observation of R1881–Binding Protein in Human Prostatic Cancer

Matsumura¹,

Naito²,

Yamaguchi³

et al. 1983

Urol Int

View full text Add to dashboard Cite

show abstract

“…The high response rate is in accordance with the observation that most human prostate cancers have a high content of androgen receptors (AR; Martelli et al 1980;Concolino et al 1982). Some recent immunohistochemical studies using antibodies to the amino-terminal domain of AR revealed that the proportion of AR positive tumour cells varied among prostate cancers; poorly differentiated prostate cancers tended to have a diminished proportion of AR positive tumour cells (Ruizeveld de Winter et al 1990;Masai et al 1990).…”

Section: Introductionsupporting

confidence: 59%

Do neuroendocrine cells in human prostate cancer express androgen receptor?

et al. 1993

View full text Add to dashboard Cite

Abstract. The presence of androgen receptors (AR) in neuroendocrine cells was investigated in benign tissue of 10 prostatectomy specimens, in 12 prostatic adenocarcinomas with focal neuroendocrine differentiation and in 1 case of a pure neuroendocrine small cell carcinoma of the prostate. Neuroendocrine cells were defined by their reactivity with an antibody to chromogranin A. Monoclonal antibody F39.4 directed against the amino-terminal domain of the AR molecule was used to detect AR. AR and chromogranin A were simultaneously visualized with a double immunofluorescence technique. The results indicate that chromogranin positive cells in both benign and malignant prostatic tissue lack detectable expression of AR. No effect of endocrine therapy was noted. These results are in agreement with the hypothesis that prostatic neuroendocrine tumour cells represent an androgen insensitive cell population, which incidentally may expand to replace the androgen-sensitive tumour cell population during androgen ablation therapy.

show abstract

“…In addition, some metastases also bound glucocorticoid (23). Martelli et al (55) also reported that primary prostatic tumors contain glucocorticoid receptors. Estrogen receptors in human prostate cancer have also been reported by a number of investigators (18, 20, 55, 74, 81, 82).…”

Section: Prostatic Carcinomamentioning

confidence: 96%